Calvert Research and CureDM Sign Collaborative Agreement

Share Article

Calvert Research signs collaborative agreement with CureDM to continue the preclinical development of CureDM's HIP2B peptide targeted for the treatment of type 1 and 2 diabetes patients.

We appreciate that Calvert has recognized the potential value of HIP to the extent that they are participating financially, as well as scientifically, toward our success

Calvert Research, LLC (a Calvert Holdings, Inc. company) announced today the signing of a collaborative agreement with CureDM to continue the preclinical development of CureDM's HIP2B peptide. Calvert and CureDM have been working together for the past two years to identify a lead candidate in the CureDM portfolio. Calvert and Cure DM will now work toward completing the required toxicology studies in order to prepare an IND submission by the end of 2009.

Located on the Lankenau Institute Medical Research campus in Wynnewood, Pennsylvania, CureDM is developing a human peptide, (HIP) targeted for the treatment of type 1 and 2 diabetes patients. HIP has a novel mechanism of action that works by stimulating the generation of new islet structures which secrete key hormones like insulin to normalize glucose levels in the blood. "We appreciate that Calvert has recognized the potential value of HIP to the extent that they are participating financially, as well as scientifically, toward our success" notes CureDM COO, Lori Upham. Calvert has invested in CureDM on a number of fronts including proof-of-efficacy studies at Calvert Laboratories (another Calvert Holdings unit), project management, and corporate development.

Dr. Dana Minnick, Director of Project Management, will oversee Calvert activities supporting the preclinical development of HIP2B. According to Dr. Minnick: "HIP2B is a novel technology with the potential to treat all forms of diabetes. Preclinical studies support the proposed mechanism of action and suggest an exciting new target for diabetes treatment complementary to current therapies."

About Calvert Research, LLC.
Established in early 2005 to work with early-stage companies to advance their lead candidate biopharmaceuticals, Calvert Research has further evolved to working closely with Technology Transfer executives of major universities across the country to identify, license, and develop novel biopharmaceutical compounds.

About Calvert Labs, Inc.
Regarded by many as the premier IND-enabling contract research organization, Calvert Laboratories has been providing contract nonclinical services for almost four decades. As a global service provider, Calvert Labs' core offerings include toxicology (acute through chronic & carcinogenicity plus reproductive and developmental), pharmacokinetics & ADME, pharmacology, safety pharmacology, immunotoxicology and immunology. Located in northeastern Pennsylvania and easily accessible by major airlines, Calvert Labs provides services to companies in the biotechnology, pharmaceutical, and chemical industrial sectors.

About Calvert Holdings, Inc.
Formed in 1996, Calvert Holdings, Inc. is a privately-held company consisting of a diverse portfolio of companies including the following: Calvert Labs, Calvert Research, Calvert BioCapital, Calvert Creative, Carolina Securities, and Calvert Cafe.

Calvert Holdings is a company of people who are passionately engaged in contributing to the future well being of the planet we live on. By analyzing how emerging discoveries and current trends will affect future global needs, we position resources and apply our skills to meet them.

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Jeff Tippett
Calvert Research
919-854-4453 ext. 202
Email >

Jeff Tippett
Visit website